Jali Medical Logo

Inspiring Treatment Through Experience

As the pioneer of Transcranial Magnetic Stimulation (TMS), Magstim is recognized as a leader in diagnostic, research & therapy solutions.

Magstim Rapid2 Therapy: rTMS treatment

What is Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy?

rTMS treatment offers a new option for patients who have failed to respond, or are unable to undergo treatment with traditional pharmaceutical medication. The treatment of rTMS therapy has gained significant clinical traction and offers a new option for treatment of patients with drug resistant major depressive disorder (MDD).

rTMS has the following benefits

  • An effective non-drug treatment
  • Proven to treat MDD**
  • Safe, non-invasive therapy
  • No systemic side effects†
  • One-off capital purchase – no pay per use disposables
  • Built by Magstim, the pioneers of TMS
Magstim Rapid2 Therapy: Unmet Need

Unmet Need & Benefits

Globally, more than 350 million people of all ages suffer from depression[1]. By the year 2030, depression is predicted to become the number one cause of disability[2]. With traditional pharmaceutical options known to have associated side effects, clinical practitioners are increasingly turning to rTMS as a fast, effective treatment option for drug resistant MDD.

Proven Efficacy without Systemic Side Effects

In depression, over 80 separate trials and 4 separate large multicenter trials have been found to show significant improvements in depression following daily prefrontal rTMS for 3-6 weeks.

Magstim Rapid2 Therapy: Response Rates

Response Rates

A multisite, naturalistic, observational study of 307 patients, who had an average failure of 2.5 adequate medication trials, received an average of 28.3 TMS therapy sessions over an average of 42 days. This study showed that 58% of patients responded positively to TMS therapy and 37.1% of patients went into remission[3].

Treatment procedure

  • An initial session which includes the determination of the patient's individual stimulation level (motor threshold determination)
  • The recommended number of treatment sessions is 5 days per week for 6 weeks, followed by 6 sessions over the next 3 weeks.

Diagnosis and initial session are performed by a psychiatrist. The remaining treatment sessions are typically conducted by trained personnel.

The FDA cleared protocol for TMS Therapy treatment consists of repeated cycles of rTMS followed by rest periods (10 Hz; 4 second trains; 26 second wait; 75 trains for a total of 3,000 stimulations per treatment session at 120% motor threshold (37.5 min).

**The Rapid2 Therapy System is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode (FDA 510k #K143531).

† There is an infrequent reported adverse effect of TMS is seizures. However, the estimated seizure risk is 0.003% of treatments, or 0.1% of patients [3]

References:
[1] Depression Fact Sheet (2012). World Health Organisation.
[2] Global Burden of Disease Report (2006). Geneva, World Health Organisation
[3] Carpenter, L et al. Transcranial Magnetic Stimulation (TMS) for Major Depression: A multisite, naturalistic, observational study of acute treatment outcomes in clinical practice (2012)

Magstim Rapid2 Therapy System

The Rapid2 Therapy System

The treatment of rTMS therapy has gained significant clinical traction and offers a new option for patient treatment, as an effective treatment for drug resistant major depressive disorder (MDD).

The Magstim Rapid2 Therapy system package includes:

  • Rapid2 Therapy Stimulator
  • Double 70mm Air Film Coil
  • Air Film Coil support stand
  • Double 70mm MT Remote Control Coil
  • Trolley cart
  • Two year warranty of parts and labour
  • Professional system installation
  • Personalized product training
  • Optional adjustable therapy chair

Magstim INSIGHT

Magstim INSIGHT®

Unique cloud-based data management platform for mental health professionals delivering TMS therapy for the treatment of drug-resistant MDD. Visit Magstim for details.

Magstim Hygiene Patient Cap

Hygiene Patient Cap

Ideal for site location marking, it allows a more repeatable coil positioning and shortens the treatment set-up time.

  • Coil Positioning & Treatment Consistency

    How does Magstim ensure accurate and consistent coil positioning?

    The Magstim therapy chair is equipped with a headrest that is fully adjustable in the x, y and z planes. The therapy chair does not use inflatable vacuum pillows as they do not prevent the patient’s head from moving. Additionally, inflatable devices may be prone to air leakage.

    We recommend the TMS patient cap as an effective option for marking off the C3 hot spot and treatment locations. The "hot spot hunting" technique is recommended as it helps identify the optimal location where hunting in a grid-like fashion is used to locate the MT assessment site. In 2004, Conforto and colleagues demonstrated that motor threshold values using the “hot spot hunting” technique can be significantly higher than the Mills-Nithi method, which approximates the final treatment coil positioning and does not take into account natural variations in cranial size and geometry.

    The Air Film Coil (AFC), which is the FDA cleared Magstim coil used for rTMS treatment, should be connected to the AFC support stand. The AFC support stand has a pneumatic arm to aid the operator in accurately maneuvering the coil during MT determination. The AFC coil should not be hand-held when running the lengthy rTMS protocol.

  • System Power & Treatment Level

    Is the Magstim D70 coil comparable to coils from other TMS device companies?

    The Magstim D70 coil should not be used for therapeutic rTMS treatment but rather the AFC. The AFC design differs from the D70mm coil and is the only FDA cleared Magstim coil used for rTMS treatment. Keeping this in mind, coil designs influence magnetic field geometry and strength as purported in the well acknowledged 2004 scientific report "Electric field properties of two commercial figure-8 coils in TMS: calculation of focality and efficiency" by Thielscher and Kammer.

    Regardless, the Magstim D70 coil has comparable focality and stimulation depth to competitor coils as reported by Thielscher and Kammer (2004) and Deng and colleagues (2013).

  • Coil Cooling & Patient Throughput

    What is the recommended cool down time for the Magstim AFC when running the FDA-cleared protocol?

    When used at 89% power output, at the ambient temperature of 23°C, we recommend a wait time of 23 min between rTMS treatment sessions. Alternatively, the use of a second coil eliminates wait time.

    The AFC is designed to run multiple FDA cleared protocols daily. Our users run approximately 6 protocols a day in their TMS clinics. To allow the coil to cool down efficiently it must remain plugged into the stimulator with the stimulator turned on between treatments.

  • Noise Levels & Patient and Operator Safety

    What safety precautions are recommended for patient and operator comfort when using the Magstim TMS stimulators?

    Sound pressure levels produced by the Magstim Stimulators may depend on the acoustic settings of the room (Dhamne et al., 2014; Pedapati et al., 2015) but is below the OSHA permissible threshold for single pulse TMS and intermittent theta burst stimulation.

    It is however, always recommended that TMS technicians as well as patients wear sound attenuation earplugs when TMS is being delivered.

How to set up your Magstim Rapid2 Therapy System

Items marked with are investigational devices and for research use only. CAUTION - Investigational Device. Limited by Federal (or United States) law to investigational use.

About Jali Medical

Established in 1991, Jali Medical is a company at the cutting edge of the emerging field of non-invasive brain stimulation. We are proud to be the US distributor for the best magnetic and electrical nerve stimulation equipment and accessories available.

Contact Us
Jali Medical, Inc.
330 Bear Hill Road, Suite 303
Waltham, MA 02451
Phone(781) 376 0008 | (888) 959 JALI
Fax(781) 376 0808
Latest News
Events
© 2017 Jali Medical, Inc. All rights reserved // site by M2P Design